Dr. Michael Poiesz

Claim this profile

Woodlands Medical Specialists

Studies Colorectal Cancer
Studies Breast Cancer
2 reported clinical trials
13 drugs studied

Area of expertise

1Colorectal Cancer
Michael Poiesz has run 1 trial for Colorectal Cancer. Some of their research focus areas include:
Stage IV
HER2 positive
Stage III
2Breast Cancer
Michael Poiesz has run 1 trial for Breast Cancer. Some of their research focus areas include:
Stage I
Stage II
HER2 negative

Affiliated Hospitals

Image of trial facility.
Woodlands Medical Specialists
Image of trial facility.
USO - Woodlands Medical Specialists

Clinical Trials Michael Poiesz is currently running

Image of trial facility.

Tucatinib + Trastuzumab + Chemotherapy

for Colorectal Cancer

This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer. This study will also determine what side effects happen when participants take this combination of drugs. A side effect is anything a drug does to the body besides treating your disease. Participants in this study have colorectal cancer that has spread through the body (metastatic) and/or cannot be removed with surgery (unresectable). Participants will be assigned randomly to the tucatinib group or standard of care group. The tucatinib group will get tucatinib, trastuzumab, and mFOLFOX6. The standard of care group will get either: * mFOLFOX6 alone, * mFOLFOX6 with bevacizumab, or * mFOLFOX6 with cetuximab mFOLFOX6 is a combination of multiple drugs. All of the drugs given in this study are used to treat this type of cancer.
Recruiting2 awards Phase 3
Image of trial facility.

Imlunestrant

for Early Breast Cancer

This trial is testing a new medication called imlunestrant to see if it works better than standard hormone treatments for certain breast cancer patients. The study focuses on patients with early-stage breast cancer that is estrogen receptor positive and HER2 negative, who have already been on hormone therapy for a period of time and are at high risk of their cancer returning. Imlunestrant works by blocking estrogen from helping cancer cells grow.
Recruiting2 awards Phase 36 criteria

More about Michael Poiesz

Clinical Trial Related1 year of experience running clinical trials · Led 2 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Michael Poiesz has experience with
  • Bevacizumab
  • Cetuximab
  • Fluorouracil
  • Leucovorin
  • Levoleucovorin
  • Oxaliplatin
Breakdown of trials Michael Poiesz has run

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Michael Poiesz specialize in?
Michael Poiesz focuses on Colorectal Cancer and Breast Cancer. In particular, much of their work with Colorectal Cancer has involved Stage IV patients, or patients who are HER2 positive.
Is Michael Poiesz currently recruiting for clinical trials?
Yes, Michael Poiesz is currently recruiting for 2 clinical trials in Pensacola Florida. If you're interested in participating, you should apply.
Are there any treatments that Michael Poiesz has studied deeply?
Yes, Michael Poiesz has studied treatments such as Bevacizumab, Cetuximab, Fluorouracil.
What is the best way to schedule an appointment with Michael Poiesz?
Apply for one of the trials that Michael Poiesz is conducting.
What is the office address of Michael Poiesz?
The office of Michael Poiesz is located at: Woodlands Medical Specialists, Pensacola, Florida 32503 United States. This is the address for their practice at the Woodlands Medical Specialists.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.